| On the importance of cotranscriptional RNA structure formation D Lai, JR Proctor, IM Meyer Rna 19 (11), 1461-1473, 2013 | 184 | 2013 |
| R- chie : a web server and R package for visualizing RNA secondary structures D Lai, JR Proctor, JYA Zhu, IM Meyer Nucleic acids research 40 (12), e95-e95, 2012 | 136 | 2012 |
| C o F old : an RNA secondary structure prediction method that takes co-transcriptional folding into account JR Proctor, IM Meyer Nucleic acids research 41 (9), e102-e102, 2013 | 94 | 2013 |
| Transient RNA structure features are evolutionarily conserved and can be computationally predicted JYA Zhu, A Steif, JR Proctor, IM Meyer Nucleic acids research 41 (12), 6273-6285, 2013 | 26 | 2013 |
| Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer JR Proctor, EM Gartner, TE Gray, RH Davies Cancer Chemotherapy and Pharmacology 90 (5), 399-408, 2022 | 6 | 2022 |
| Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature JR Proctor, H Wong Clinical and Translational Science 17 (1), e13676, 2024 | 4 | 2024 |
| Increasing the therapeutic index of IL12 by engineering for tumor specific protease activation JL Bishop, R Blackler, G Volkers, M Poffenberger, I Yu, J Smith, ... Cancer Research 81 (13_Supplement), 1788-1788, 2021 | 4 | 2021 |
| Clinical study design strategies to mitigate confounding effects of time‐dependent clearance on dose optimization of therapeutic antibodies JR Proctor, H Wong CPT: Pharmacometrics & Systems Pharmacology, 2024 | | 2024 |
| ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity MC Poffenberger, JL Bishop, RJ Blackler, KG Haworth, S Booth, ... Cancer Research 83 (7_Supplement), 2935-2935, 2023 | | 2023 |
